nodes	percent_of_prediction	percent_of_DWPC	metapath
Fulvestrant—breast cancer—bone cancer	0.675	1	CtDrD
Fulvestrant—CYP3A4—bone cancer	0.232	1	CbGaD
Fulvestrant—EPHX2—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00432	0.0872	CbGpPWpGaD
Fulvestrant—NR1H4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00248	0.0501	CbGpPWpGaD
Fulvestrant—NR1H4—skull—bone cancer	0.00236	0.452	CbGeAlD
Fulvestrant—EPHX2—Metapathway biotransformation—CYP4V2—bone cancer	0.00195	0.0392	CbGpPWpGaD
Fulvestrant—ESRRA—Nuclear Receptors—NR1I2—bone cancer	0.00179	0.036	CbGpPWpGaD
Fulvestrant—Estradiol—NR1I2—bone cancer	0.00154	0.835	CrCbGaD
Fulvestrant—NR1H4—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.00145	0.0293	CbGpPWpGaD
Fulvestrant—NR1H4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00143	0.0288	CbGpPWpGaD
Fulvestrant—ESRRA—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00141	0.0285	CbGpPWpGaD
Fulvestrant—NR1H4—Farnesoid X Receptor  Pathway—CYP3A4—bone cancer	0.00133	0.0268	CbGpPWpGaD
Fulvestrant—ESR1—LKB1 signaling events—ETV4—bone cancer	0.0013	0.0263	CbGpPWpGaD
Fulvestrant—ESR1—Signaling events mediated by HDAC Class II—BCOR—bone cancer	0.00128	0.0259	CbGpPWpGaD
Fulvestrant—ESR2—Nuclear Receptors—NR1I2—bone cancer	0.00114	0.0229	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—FEV—bone cancer	0.00109	0.0219	CbGpPWpGaD
Fulvestrant—NR1H4—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00103	0.0208	CbGpPWpGaD
Fulvestrant—ESR1—periosteum—bone cancer	0.000905	0.173	CbGeAlD
Fulvestrant—ESR2—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.000899	0.0181	CbGpPWpGaD
Fulvestrant—Injection site haemorrhage—Epirubicin—bone cancer	0.000857	0.0238	CcSEcCtD
Fulvestrant—NR1H4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000834	0.0168	CbGpPWpGaD
Fulvestrant—Injection site haemorrhage—Doxorubicin—bone cancer	0.000793	0.022	CcSEcCtD
Fulvestrant—Venous thromboembolism—Epirubicin—bone cancer	0.000786	0.0218	CcSEcCtD
Fulvestrant—Venous thromboembolism—Doxorubicin—bone cancer	0.000727	0.0202	CcSEcCtD
Fulvestrant—ESRRA—Generic Transcription Pathway—ZNF77—bone cancer	0.00072	0.0145	CbGpPWpGaD
Fulvestrant—NR1H4—Orphan transporters—TUBB4B—bone cancer	0.000716	0.0144	CbGpPWpGaD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—GNA11—bone cancer	0.000689	0.0139	CbGpPWpGaD
Fulvestrant—NR1H4—Orphan transporters—TUBB2A—bone cancer	0.000618	0.0125	CbGpPWpGaD
Fulvestrant—ESR1—Signaling events mediated by HDAC Class II—TUBB2A—bone cancer	0.000607	0.0122	CbGpPWpGaD
Fulvestrant—ESR1—Nuclear Receptors—NR1I2—bone cancer	0.000573	0.0116	CbGpPWpGaD
Fulvestrant—Infection—Carboplatin—bone cancer	0.000543	0.0151	CcSEcCtD
Fulvestrant—NR1H4—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000529	0.0107	CbGpPWpGaD
Fulvestrant—NR1H4—Generic Transcription Pathway—ZNF77—bone cancer	0.000526	0.0106	CbGpPWpGaD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—IGF1R—bone cancer	0.000503	0.0101	CbGpPWpGaD
Fulvestrant—NR1H4—connective tissue—bone cancer	0.000502	0.0958	CbGeAlD
Fulvestrant—Leukorrhea—Epirubicin—bone cancer	0.000492	0.0137	CcSEcCtD
Fulvestrant—ESR2—Ovarian Infertility Genes—CDK4—bone cancer	0.000472	0.00953	CbGpPWpGaD
Fulvestrant—Pain—Carboplatin—bone cancer	0.000468	0.013	CcSEcCtD
Fulvestrant—EPHX2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000464	0.00937	CbGpPWpGaD
Fulvestrant—ESR2—Generic Transcription Pathway—ZNF77—bone cancer	0.000458	0.00925	CbGpPWpGaD
Fulvestrant—Embolism venous—Epirubicin—bone cancer	0.000458	0.0127	CcSEcCtD
Fulvestrant—Vaginal moniliasis—Epirubicin—bone cancer	0.000458	0.0127	CcSEcCtD
Fulvestrant—Leukorrhea—Doxorubicin—bone cancer	0.000456	0.0126	CcSEcCtD
Fulvestrant—ESR1—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.000453	0.00914	CbGpPWpGaD
Fulvestrant—Vulvovaginal candidiasis—Epirubicin—bone cancer	0.000439	0.0122	CcSEcCtD
Fulvestrant—Body temperature increased—Carboplatin—bone cancer	0.000432	0.012	CcSEcCtD
Fulvestrant—NR1H4—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000429	0.00865	CbGpPWpGaD
Fulvestrant—Vaginal moniliasis—Doxorubicin—bone cancer	0.000423	0.0118	CcSEcCtD
Fulvestrant—Embolism venous—Doxorubicin—bone cancer	0.000423	0.0118	CcSEcCtD
Fulvestrant—Vulvovaginal mycotic infection—Epirubicin—bone cancer	0.000422	0.0117	CcSEcCtD
Fulvestrant—Vulvovaginal candidiasis—Doxorubicin—bone cancer	0.000406	0.0113	CcSEcCtD
Fulvestrant—Vaginal discharge—Methotrexate—bone cancer	0.000406	0.0113	CcSEcCtD
Fulvestrant—Vulvovaginal mycotic infection—Doxorubicin—bone cancer	0.000391	0.0108	CcSEcCtD
Fulvestrant—EPHX2—Metapathway biotransformation—CYP3A4—bone cancer	0.000385	0.00776	CbGpPWpGaD
Fulvestrant—Vaginal discharge—Epirubicin—bone cancer	0.00038	0.0105	CcSEcCtD
Fulvestrant—Pelvic pain—Epirubicin—bone cancer	0.00038	0.0105	CcSEcCtD
Fulvestrant—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000378	0.00762	CbGpPWpGaD
Fulvestrant—ESR1—Signaling mediated by p38-alpha and p38-beta—ATF1—bone cancer	0.000367	0.0074	CbGpPWpGaD
Fulvestrant—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000356	0.00717	CbGpPWpGaD
Fulvestrant—Pelvic pain—Doxorubicin—bone cancer	0.000351	0.00975	CcSEcCtD
Fulvestrant—Vaginal discharge—Doxorubicin—bone cancer	0.000351	0.00975	CcSEcCtD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—GNA11—bone cancer	0.000348	0.00701	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—ZNF77—bone cancer	0.000347	0.007	CbGpPWpGaD
Fulvestrant—EPHX2—Metapathway biotransformation—GSTP1—bone cancer	0.000329	0.00664	CbGpPWpGaD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—MMP2—bone cancer	0.000323	0.00652	CbGpPWpGaD
Fulvestrant—ESR1—Estrogen Receptor Pathway—JUN—bone cancer	0.000316	0.00636	CbGpPWpGaD
Fulvestrant—Vaginal haemorrhage—Epirubicin—bone cancer	0.000312	0.00866	CcSEcCtD
Fulvestrant—ESR1—FOXM1 transcription factor network—CHEK2—bone cancer	0.000305	0.00615	CbGpPWpGaD
Fulvestrant—Estradiol—CYP3A4—bone cancer	0.000304	0.165	CrCbGaD
Fulvestrant—EPHX2—tendon—bone cancer	0.000301	0.0576	CbGeAlD
Fulvestrant—ESR1—Regulation of Telomerase—WT1—bone cancer	0.000298	0.00601	CbGpPWpGaD
Fulvestrant—Breast disorder—Cisplatin—bone cancer	0.000295	0.00819	CcSEcCtD
Fulvestrant—Vaginal haemorrhage—Doxorubicin—bone cancer	0.000289	0.00801	CcSEcCtD
Fulvestrant—Injection site pain—Epirubicin—bone cancer	0.000283	0.00785	CcSEcCtD
Fulvestrant—ESR1—Estrogen signaling pathway—BRAF—bone cancer	0.000275	0.00554	CbGpPWpGaD
Fulvestrant—ESRRA—tendon—bone cancer	0.000264	0.0504	CbGeAlD
Fulvestrant—Vasodilation procedure—Epirubicin—bone cancer	0.000263	0.00729	CcSEcCtD
Fulvestrant—Vasodilation—Epirubicin—bone cancer	0.000263	0.00729	CcSEcCtD
Fulvestrant—Injection site pain—Doxorubicin—bone cancer	0.000262	0.00726	CcSEcCtD
Fulvestrant—Hepatic enzyme increased—Methotrexate—bone cancer	0.000261	0.00724	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000259	0.00522	CbGpPWpGaD
Fulvestrant—ESR1—FOXM1 transcription factor network—BRCA2—bone cancer	0.000258	0.00521	CbGpPWpGaD
Fulvestrant—ESRRA—bone marrow—bone cancer	0.000256	0.0488	CbGeAlD
Fulvestrant—ESRRA—spinal cord—bone cancer	0.000255	0.0486	CbGeAlD
Fulvestrant—Inflammation—Methotrexate—bone cancer	0.000254	0.00706	CcSEcCtD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—IGF1R—bone cancer	0.000254	0.00511	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—ZNF77—bone cancer	0.000253	0.00511	CbGpPWpGaD
Fulvestrant—Cough increased—Epirubicin—bone cancer	0.000252	0.007	CcSEcCtD
Fulvestrant—Blood bilirubin increased—Epirubicin—bone cancer	0.000244	0.00678	CcSEcCtD
Fulvestrant—ESRRA—Generic Transcription Pathway—NR1I2—bone cancer	0.000244	0.00492	CbGpPWpGaD
Fulvestrant—Vasodilation—Doxorubicin—bone cancer	0.000243	0.00675	CcSEcCtD
Fulvestrant—Vasodilation procedure—Doxorubicin—bone cancer	0.000243	0.00675	CcSEcCtD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—MMP9—bone cancer	0.000243	0.0049	CbGpPWpGaD
Fulvestrant—Bone pain—Epirubicin—bone cancer	0.000241	0.00669	CcSEcCtD
Fulvestrant—Inflammation—Epirubicin—bone cancer	0.000238	0.00661	CcSEcCtD
Fulvestrant—Hepatobiliary disease—Cisplatin—bone cancer	0.000238	0.0066	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—NDUFA12—bone cancer	0.000234	0.00472	CbGpPWpGaD
Fulvestrant—Musculoskeletal pain—Epirubicin—bone cancer	0.000234	0.00649	CcSEcCtD
Fulvestrant—Cough increased—Doxorubicin—bone cancer	0.000233	0.00648	CcSEcCtD
Fulvestrant—ESR1—Generic Transcription Pathway—ZNF77—bone cancer	0.000231	0.00466	CbGpPWpGaD
Fulvestrant—ESR2—connective tissue—bone cancer	0.00023	0.044	CbGeAlD
Fulvestrant—Injection site reaction—Epirubicin—bone cancer	0.00023	0.00637	CcSEcCtD
Fulvestrant—NR1H4—Biological oxidations—CYP3A4—bone cancer	0.000228	0.0046	CbGpPWpGaD
Fulvestrant—Blood bilirubin increased—Doxorubicin—bone cancer	0.000226	0.00627	CcSEcCtD
Fulvestrant—Bone pain—Doxorubicin—bone cancer	0.000223	0.00619	CcSEcCtD
Fulvestrant—Connective tissue disorder—Cisplatin—bone cancer	0.000222	0.00616	CcSEcCtD
Fulvestrant—ESR2—Gene Expression—ZNF77—bone cancer	0.000221	0.00445	CbGpPWpGaD
Fulvestrant—Inflammation—Doxorubicin—bone cancer	0.00022	0.00611	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.00022	0.00444	CbGpPWpGaD
Fulvestrant—Musculoskeletal pain—Doxorubicin—bone cancer	0.000216	0.006	CcSEcCtD
Fulvestrant—Injection site reaction—Doxorubicin—bone cancer	0.000212	0.0059	CcSEcCtD
Fulvestrant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000204	0.00412	CbGpPWpGaD
Fulvestrant—Immune system disorder—Cisplatin—bone cancer	0.000204	0.00566	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.0002	0.00404	CbGpPWpGaD
Fulvestrant—ESR1—Estrogen signaling pathway—JUN—bone cancer	0.0002	0.00403	CbGpPWpGaD
Fulvestrant—Hepatic failure—Methotrexate—bone cancer	0.000199	0.00553	CcSEcCtD
Fulvestrant—Malnutrition—Cisplatin—bone cancer	0.000197	0.00546	CcSEcCtD
Fulvestrant—NR1H4—Biological oxidations—GSTP1—bone cancer	0.000195	0.00393	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—NT5C3A—bone cancer	0.000194	0.00391	CbGpPWpGaD
Fulvestrant—ESR1—FOXM1 transcription factor network—CDK4—bone cancer	0.000192	0.00387	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—NDUFA12—bone cancer	0.000187	0.00377	CbGpPWpGaD
Fulvestrant—Hepatic failure—Epirubicin—bone cancer	0.000187	0.00518	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000183	0.00368	CbGpPWpGaD
Fulvestrant—Anaemia—Cisplatin—bone cancer	0.000182	0.00504	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.00018	0.00363	CbGpPWpGaD
Fulvestrant—Hot flush—Epirubicin—bone cancer	0.000179	0.00497	CcSEcCtD
Fulvestrant—NR1H4—Generic Transcription Pathway—NR1I2—bone cancer	0.000178	0.00359	CbGpPWpGaD
Fulvestrant—Menopausal symptoms—Epirubicin—bone cancer	0.000178	0.00493	CcSEcCtD
Fulvestrant—Leukopenia—Cisplatin—bone cancer	0.000176	0.00488	CcSEcCtD
Fulvestrant—ESR2—Validated nuclear estrogen receptor alpha network—JUN—bone cancer	0.000175	0.00353	CbGpPWpGaD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000175	0.00352	CbGpPWpGaD
Fulvestrant—Hepatic failure—Doxorubicin—bone cancer	0.000173	0.00479	CcSEcCtD
Fulvestrant—ESRRA—Gene Expression—FUS—bone cancer	0.000169	0.00342	CbGpPWpGaD
Fulvestrant—Pain in extremity—Epirubicin—bone cancer	0.000168	0.00465	CcSEcCtD
Fulvestrant—Myalgia—Cisplatin—bone cancer	0.000167	0.00464	CcSEcCtD
Fulvestrant—Anxiety—Cisplatin—bone cancer	0.000167	0.00463	CcSEcCtD
Fulvestrant—ESR1—FOXM1 transcription factor network—RB1—bone cancer	0.000167	0.00336	CbGpPWpGaD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000166	0.00461	CcSEcCtD
Fulvestrant—Hot flush—Doxorubicin—bone cancer	0.000166	0.0046	CcSEcCtD
Fulvestrant—Menopausal symptoms—Doxorubicin—bone cancer	0.000164	0.00456	CcSEcCtD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—MMP2—bone cancer	0.000163	0.00329	CbGpPWpGaD
Fulvestrant—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000163	0.00328	CbGpPWpGaD
Fulvestrant—Breast disorder—Methotrexate—bone cancer	0.000162	0.00449	CcSEcCtD
Fulvestrant—ESR1—FOXM1 transcription factor network—MMP2—bone cancer	0.00016	0.00322	CbGpPWpGaD
Fulvestrant—Infection—Cisplatin—bone cancer	0.000159	0.00442	CcSEcCtD
Fulvestrant—ESR1—Signaling mediated by p38-alpha and p38-beta—PTGS2—bone cancer	0.000158	0.0032	CbGpPWpGaD
Fulvestrant—ESR1—connective tissue—bone cancer	0.000158	0.0301	CbGeAlD
Fulvestrant—Nervous system disorder—Cisplatin—bone cancer	0.000157	0.00437	CcSEcCtD
Fulvestrant—Skin disorder—Cisplatin—bone cancer	0.000156	0.00432	CcSEcCtD
Fulvestrant—ESR2—Generic Transcription Pathway—NR1I2—bone cancer	0.000155	0.00313	CbGpPWpGaD
Fulvestrant—Pain in extremity—Doxorubicin—bone cancer	0.000155	0.0043	CcSEcCtD
Fulvestrant—Hyperhidrosis—Cisplatin—bone cancer	0.000155	0.0043	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000155	0.00313	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—NT5C3A—bone cancer	0.000155	0.00312	CbGpPWpGaD
Fulvestrant—ESR1—ATF-2 transcription factor network—PLAU—bone cancer	0.000155	0.00312	CbGpPWpGaD
Fulvestrant—Anorexia—Cisplatin—bone cancer	0.000153	0.00424	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000153	0.00308	CbGpPWpGaD
Fulvestrant—Breast disorder—Epirubicin—bone cancer	0.000151	0.0042	CcSEcCtD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000151	0.00304	CbGpPWpGaD
Fulvestrant—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000146	0.00406	CcSEcCtD
Fulvestrant—ESR1—ATF-2 transcription factor network—CDK4—bone cancer	0.000146	0.00295	CbGpPWpGaD
Fulvestrant—Influenza—Epirubicin—bone cancer	0.000145	0.00402	CcSEcCtD
Fulvestrant—Paraesthesia—Cisplatin—bone cancer	0.000144	0.004	CcSEcCtD
Fulvestrant—Dyspnoea—Cisplatin—bone cancer	0.000143	0.00397	CcSEcCtD
Fulvestrant—ESR1—Signaling mediated by p38-alpha and p38-beta—JUN—bone cancer	0.000143	0.00288	CbGpPWpGaD
Fulvestrant—Breast disorder—Doxorubicin—bone cancer	0.00014	0.00389	CcSEcCtD
Fulvestrant—Decreased appetite—Cisplatin—bone cancer	0.000139	0.00387	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Cisplatin—bone cancer	0.000138	0.00384	CcSEcCtD
Fulvestrant—Infestation NOS—Methotrexate—bone cancer	0.000138	0.00383	CcSEcCtD
Fulvestrant—Infestation—Methotrexate—bone cancer	0.000138	0.00383	CcSEcCtD
Fulvestrant—Depression—Methotrexate—bone cancer	0.000138	0.00382	CcSEcCtD
Fulvestrant—Pain—Cisplatin—bone cancer	0.000137	0.00381	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—NDUFA12—bone cancer	0.000137	0.00276	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—PLAU—bone cancer	0.000135	0.00272	CbGpPWpGaD
Fulvestrant—Influenza—Doxorubicin—bone cancer	0.000134	0.00372	CcSEcCtD
Fulvestrant—Sweating—Methotrexate—bone cancer	0.000132	0.00367	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000131	0.00263	CbGpPWpGaD
Fulvestrant—Hepatobiliary disease—Methotrexate—bone cancer	0.000131	0.00362	CcSEcCtD
Fulvestrant—Infestation—Epirubicin—bone cancer	0.000129	0.00359	CcSEcCtD
Fulvestrant—Infestation NOS—Epirubicin—bone cancer	0.000129	0.00359	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000127	0.00257	CbGpPWpGaD
Fulvestrant—ESR1—ATF-2 transcription factor network—RB1—bone cancer	0.000127	0.00256	CbGpPWpGaD
Fulvestrant—Body temperature increased—Cisplatin—bone cancer	0.000127	0.00352	CcSEcCtD
Fulvestrant—Urinary tract infection—Epirubicin—bone cancer	0.000126	0.00348	CcSEcCtD
Fulvestrant—Haemoglobin—Methotrexate—bone cancer	0.000125	0.00346	CcSEcCtD
Fulvestrant—Haemorrhage—Methotrexate—bone cancer	0.000124	0.00344	CcSEcCtD
Fulvestrant—Hepatitis—Methotrexate—bone cancer	0.000124	0.00344	CcSEcCtD
Fulvestrant—Sweating—Epirubicin—bone cancer	0.000124	0.00344	CcSEcCtD
Fulvestrant—NR1H4—Gene Expression—FUS—bone cancer	0.000124	0.0025	CbGpPWpGaD
Fulvestrant—Pharyngitis—Methotrexate—bone cancer	0.000123	0.00341	CcSEcCtD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—MMP9—bone cancer	0.000123	0.00247	CbGpPWpGaD
Fulvestrant—Hepatobiliary disease—Epirubicin—bone cancer	0.000122	0.00339	CcSEcCtD
Fulvestrant—ESR1—ATF-2 transcription factor network—MMP2—bone cancer	0.000122	0.00246	CbGpPWpGaD
Fulvestrant—Infestation—Doxorubicin—bone cancer	0.00012	0.00332	CcSEcCtD
Fulvestrant—Infestation NOS—Doxorubicin—bone cancer	0.00012	0.00332	CcSEcCtD
Fulvestrant—ESR1—FOXA1 transcription factor network—JUN—bone cancer	0.000119	0.0024	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Cisplatin—bone cancer	0.000118	0.00328	CcSEcCtD
Fulvestrant—ESRRA—Gene Expression—NR1I2—bone cancer	0.000117	0.00237	CbGpPWpGaD
Fulvestrant—Haemoglobin—Epirubicin—bone cancer	0.000117	0.00323	CcSEcCtD
Fulvestrant—Urinary tract infection—Doxorubicin—bone cancer	0.000116	0.00322	CcSEcCtD
Fulvestrant—Haemorrhage—Epirubicin—bone cancer	0.000116	0.00322	CcSEcCtD
Fulvestrant—Hepatitis—Epirubicin—bone cancer	0.000116	0.00322	CcSEcCtD
Fulvestrant—Asthenia—Cisplatin—bone cancer	0.000115	0.00319	CcSEcCtD
Fulvestrant—Pharyngitis—Epirubicin—bone cancer	0.000115	0.00319	CcSEcCtD
Fulvestrant—Sweating—Doxorubicin—bone cancer	0.000115	0.00318	CcSEcCtD
Fulvestrant—Oedema peripheral—Epirubicin—bone cancer	0.000114	0.00317	CcSEcCtD
Fulvestrant—Connective tissue disorder—Epirubicin—bone cancer	0.000114	0.00316	CcSEcCtD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.000114	0.0023	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—CDK4—bone cancer	0.000113	0.00229	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—NT5C3A—bone cancer	0.000113	0.00228	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000113	0.00228	CbGpPWpGaD
Fulvestrant—Hepatobiliary disease—Doxorubicin—bone cancer	0.000113	0.00314	CcSEcCtD
Fulvestrant—Angiopathy—Methotrexate—bone cancer	0.000112	0.00312	CcSEcCtD
Fulvestrant—Immune system disorder—Methotrexate—bone cancer	0.000112	0.00311	CcSEcCtD
Fulvestrant—ESR1—Gene Expression—ZNF77—bone cancer	0.000111	0.00224	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000111	0.00224	CbGpPWpGaD
Fulvestrant—Diarrhoea—Cisplatin—bone cancer	0.00011	0.00305	CcSEcCtD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.00011	0.00221	CbGpPWpGaD
Fulvestrant—Malnutrition—Methotrexate—bone cancer	0.000108	0.00299	CcSEcCtD
Fulvestrant—Haemoglobin—Doxorubicin—bone cancer	0.000108	0.00299	CcSEcCtD
Fulvestrant—ESR2—Gene Expression—FUS—bone cancer	0.000108	0.00217	CbGpPWpGaD
Fulvestrant—Hepatitis—Doxorubicin—bone cancer	0.000107	0.00298	CcSEcCtD
Fulvestrant—Haemorrhage—Doxorubicin—bone cancer	0.000107	0.00298	CcSEcCtD
Fulvestrant—Pharyngitis—Doxorubicin—bone cancer	0.000106	0.00296	CcSEcCtD
Fulvestrant—Oedema peripheral—Doxorubicin—bone cancer	0.000106	0.00293	CcSEcCtD
Fulvestrant—Connective tissue disorder—Doxorubicin—bone cancer	0.000105	0.00293	CcSEcCtD
Fulvestrant—Angiopathy—Epirubicin—bone cancer	0.000105	0.00292	CcSEcCtD
Fulvestrant—Immune system disorder—Epirubicin—bone cancer	0.000105	0.00291	CcSEcCtD
Fulvestrant—Back pain—Methotrexate—bone cancer	0.000104	0.0029	CcSEcCtD
Fulvestrant—Vomiting—Cisplatin—bone cancer	0.000102	0.00283	CcSEcCtD
Fulvestrant—Rash—Cisplatin—bone cancer	0.000101	0.00281	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000101	0.00204	CbGpPWpGaD
Fulvestrant—Dermatitis—Cisplatin—bone cancer	0.000101	0.0028	CcSEcCtD
Fulvestrant—Malnutrition—Epirubicin—bone cancer	0.000101	0.0028	CcSEcCtD
Fulvestrant—Anaemia—Methotrexate—bone cancer	9.97e-05	0.00277	CcSEcCtD
Fulvestrant—Back pain—Epirubicin—bone cancer	9.76e-05	0.00271	CcSEcCtD
Fulvestrant—Angiopathy—Doxorubicin—bone cancer	9.73e-05	0.0027	CcSEcCtD
Fulvestrant—Immune system disorder—Doxorubicin—bone cancer	9.69e-05	0.00269	CcSEcCtD
Fulvestrant—Vertigo—Methotrexate—bone cancer	9.69e-05	0.00269	CcSEcCtD
Fulvestrant—Leukopenia—Methotrexate—bone cancer	9.65e-05	0.00268	CcSEcCtD
Fulvestrant—Nausea—Cisplatin—bone cancer	9.53e-05	0.00264	CcSEcCtD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	9.5e-05	0.00192	CbGpPWpGaD
Fulvestrant—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—bone cancer	9.43e-05	0.0019	CbGpPWpGaD
Fulvestrant—Cough—Methotrexate—bone cancer	9.41e-05	0.00261	CcSEcCtD
Fulvestrant—ESR1—ATF-2 transcription factor network—JUN—bone cancer	9.41e-05	0.0019	CbGpPWpGaD
Fulvestrant—Malnutrition—Doxorubicin—bone cancer	9.34e-05	0.00259	CcSEcCtD
Fulvestrant—Anaemia—Epirubicin—bone cancer	9.33e-05	0.00259	CcSEcCtD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—BRCA2—bone cancer	9.28e-05	0.00187	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	9.2e-05	0.00186	CbGpPWpGaD
Fulvestrant—Arthralgia—Methotrexate—bone cancer	9.18e-05	0.00255	CcSEcCtD
Fulvestrant—Chest pain—Methotrexate—bone cancer	9.18e-05	0.00255	CcSEcCtD
Fulvestrant—Myalgia—Methotrexate—bone cancer	9.18e-05	0.00255	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	9.12e-05	0.00253	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	9.08e-05	0.00183	CbGpPWpGaD
Fulvestrant—Vertigo—Epirubicin—bone cancer	9.07e-05	0.00252	CcSEcCtD
Fulvestrant—Leukopenia—Epirubicin—bone cancer	9.04e-05	0.00251	CcSEcCtD
Fulvestrant—Back pain—Doxorubicin—bone cancer	9.03e-05	0.00251	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	9.03e-05	0.00182	CbGpPWpGaD
Fulvestrant—ESR1—Validated nuclear estrogen receptor alpha network—JUN—bone cancer	8.82e-05	0.00178	CbGpPWpGaD
Fulvestrant—Cough—Epirubicin—bone cancer	8.81e-05	0.00244	CcSEcCtD
Fulvestrant—Infection—Methotrexate—bone cancer	8.75e-05	0.00243	CcSEcCtD
Fulvestrant—ESRRA—Gene Expression—EIF2S1—bone cancer	8.67e-05	0.00175	CbGpPWpGaD
Fulvestrant—Nervous system disorder—Methotrexate—bone cancer	8.63e-05	0.0024	CcSEcCtD
Fulvestrant—Anaemia—Doxorubicin—bone cancer	8.63e-05	0.0024	CcSEcCtD
Fulvestrant—Chest pain—Epirubicin—bone cancer	8.59e-05	0.00239	CcSEcCtD
Fulvestrant—Arthralgia—Epirubicin—bone cancer	8.59e-05	0.00239	CcSEcCtD
Fulvestrant—Myalgia—Epirubicin—bone cancer	8.59e-05	0.00239	CcSEcCtD
Fulvestrant—NR1H4—Gene Expression—NR1I2—bone cancer	8.58e-05	0.00173	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—JUN—bone cancer	8.57e-05	0.00173	CbGpPWpGaD
Fulvestrant—Anxiety—Epirubicin—bone cancer	8.56e-05	0.00238	CcSEcCtD
Fulvestrant—Skin disorder—Methotrexate—bone cancer	8.55e-05	0.00237	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	8.53e-05	0.00237	CcSEcCtD
Fulvestrant—Hyperhidrosis—Methotrexate—bone cancer	8.51e-05	0.00236	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—ENO2—bone cancer	8.49e-05	0.00171	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—JUN—bone cancer	8.4e-05	0.00169	CbGpPWpGaD
Fulvestrant—Vertigo—Doxorubicin—bone cancer	8.39e-05	0.00233	CcSEcCtD
Fulvestrant—Anorexia—Methotrexate—bone cancer	8.39e-05	0.00233	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	8.39e-05	0.00169	CbGpPWpGaD
Fulvestrant—Leukopenia—Doxorubicin—bone cancer	8.36e-05	0.00232	CcSEcCtD
Fulvestrant—ESR1—AP-1 transcription factor network—JUN—bone cancer	8.21e-05	0.00166	CbGpPWpGaD
Fulvestrant—Infection—Epirubicin—bone cancer	8.18e-05	0.00227	CcSEcCtD
Fulvestrant—Cough—Doxorubicin—bone cancer	8.15e-05	0.00226	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	8.09e-05	0.00163	CbGpPWpGaD
Fulvestrant—Nervous system disorder—Epirubicin—bone cancer	8.08e-05	0.00224	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Methotrexate—bone cancer	8.02e-05	0.00223	CcSEcCtD
Fulvestrant—Skin disorder—Epirubicin—bone cancer	8e-05	0.00222	CcSEcCtD
Fulvestrant—ESR1—LKB1 signaling events—TP53—bone cancer	8e-05	0.00161	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—MMP9—bone cancer	7.99e-05	0.00161	CbGpPWpGaD
Fulvestrant—Hyperhidrosis—Epirubicin—bone cancer	7.96e-05	0.00221	CcSEcCtD
Fulvestrant—Insomnia—Methotrexate—bone cancer	7.96e-05	0.00221	CcSEcCtD
Fulvestrant—Chest pain—Doxorubicin—bone cancer	7.95e-05	0.00221	CcSEcCtD
Fulvestrant—Arthralgia—Doxorubicin—bone cancer	7.95e-05	0.00221	CcSEcCtD
Fulvestrant—Myalgia—Doxorubicin—bone cancer	7.95e-05	0.00221	CcSEcCtD
Fulvestrant—Anxiety—Doxorubicin—bone cancer	7.92e-05	0.0022	CcSEcCtD
Fulvestrant—Paraesthesia—Methotrexate—bone cancer	7.9e-05	0.00219	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	7.9e-05	0.00219	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—DHFR—bone cancer	7.87e-05	0.00159	CbGpPWpGaD
Fulvestrant—Anorexia—Epirubicin—bone cancer	7.85e-05	0.00218	CcSEcCtD
Fulvestrant—Dyspnoea—Methotrexate—bone cancer	7.85e-05	0.00218	CcSEcCtD
Fulvestrant—ESR1—Generic Transcription Pathway—NR1I2—bone cancer	7.83e-05	0.00158	CbGpPWpGaD
Fulvestrant—Dyspepsia—Methotrexate—bone cancer	7.75e-05	0.00215	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	7.69e-05	0.00155	CbGpPWpGaD
Fulvestrant—Decreased appetite—Methotrexate—bone cancer	7.65e-05	0.00212	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Methotrexate—bone cancer	7.6e-05	0.00211	CcSEcCtD
Fulvestrant—Fatigue—Methotrexate—bone cancer	7.59e-05	0.00211	CcSEcCtD
Fulvestrant—Infection—Doxorubicin—bone cancer	7.57e-05	0.0021	CcSEcCtD
Fulvestrant—ESRRA—Gene Expression—EZH2—bone cancer	7.53e-05	0.00152	CbGpPWpGaD
Fulvestrant—Pain—Methotrexate—bone cancer	7.53e-05	0.00209	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Epirubicin—bone cancer	7.51e-05	0.00208	CcSEcCtD
Fulvestrant—Nervous system disorder—Doxorubicin—bone cancer	7.47e-05	0.00207	CcSEcCtD
Fulvestrant—ESR2—Gene Expression—NR1I2—bone cancer	7.47e-05	0.00151	CbGpPWpGaD
Fulvestrant—Insomnia—Epirubicin—bone cancer	7.45e-05	0.00207	CcSEcCtD
Fulvestrant—Skin disorder—Doxorubicin—bone cancer	7.4e-05	0.00206	CcSEcCtD
Fulvestrant—Paraesthesia—Epirubicin—bone cancer	7.4e-05	0.00205	CcSEcCtD
Fulvestrant—Hyperhidrosis—Doxorubicin—bone cancer	7.37e-05	0.00205	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—GNA11—bone cancer	7.36e-05	0.00148	CbGpPWpGaD
Fulvestrant—Dyspnoea—Epirubicin—bone cancer	7.34e-05	0.00204	CcSEcCtD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—JUN—bone cancer	7.3e-05	0.00147	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	7.29e-05	0.00147	CbGpPWpGaD
Fulvestrant—Anorexia—Doxorubicin—bone cancer	7.27e-05	0.00202	CcSEcCtD
Fulvestrant—Dyspepsia—Epirubicin—bone cancer	7.25e-05	0.00201	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Methotrexate—bone cancer	7.2e-05	0.002	CcSEcCtD
Fulvestrant—Decreased appetite—Epirubicin—bone cancer	7.16e-05	0.00199	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Epirubicin—bone cancer	7.11e-05	0.00197	CcSEcCtD
Fulvestrant—Fatigue—Epirubicin—bone cancer	7.1e-05	0.00197	CcSEcCtD
Fulvestrant—Pain—Epirubicin—bone cancer	7.04e-05	0.00196	CcSEcCtD
Fulvestrant—Constipation—Epirubicin—bone cancer	7.04e-05	0.00196	CcSEcCtD
Fulvestrant—Urticaria—Methotrexate—bone cancer	6.99e-05	0.00194	CcSEcCtD
Fulvestrant—Body temperature increased—Methotrexate—bone cancer	6.96e-05	0.00193	CcSEcCtD
Fulvestrant—Abdominal pain—Methotrexate—bone cancer	6.96e-05	0.00193	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Doxorubicin—bone cancer	6.94e-05	0.00193	CcSEcCtD
Fulvestrant—Insomnia—Doxorubicin—bone cancer	6.89e-05	0.00191	CcSEcCtD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CDK4—bone cancer	6.89e-05	0.00139	CbGpPWpGaD
Fulvestrant—Paraesthesia—Doxorubicin—bone cancer	6.84e-05	0.0019	CcSEcCtD
Fulvestrant—Dyspnoea—Doxorubicin—bone cancer	6.8e-05	0.00189	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—ENO2—bone cancer	6.79e-05	0.00137	CbGpPWpGaD
Fulvestrant—Gastrointestinal pain—Epirubicin—bone cancer	6.74e-05	0.00187	CcSEcCtD
Fulvestrant—Dyspepsia—Doxorubicin—bone cancer	6.71e-05	0.00186	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—CYP3A4—bone cancer	6.67e-05	0.00135	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	6.64e-05	0.00134	CbGpPWpGaD
Fulvestrant—Decreased appetite—Doxorubicin—bone cancer	6.63e-05	0.00184	CcSEcCtD
Fulvestrant—ESR1—Regulation of Telomerase—EGFR—bone cancer	6.6e-05	0.00133	CbGpPWpGaD
Fulvestrant—Gastrointestinal disorder—Doxorubicin—bone cancer	6.58e-05	0.00183	CcSEcCtD
Fulvestrant—Fatigue—Doxorubicin—bone cancer	6.57e-05	0.00182	CcSEcCtD
Fulvestrant—Urticaria—Epirubicin—bone cancer	6.54e-05	0.00182	CcSEcCtD
Fulvestrant—Constipation—Doxorubicin—bone cancer	6.52e-05	0.00181	CcSEcCtD
Fulvestrant—Pain—Doxorubicin—bone cancer	6.52e-05	0.00181	CcSEcCtD
Fulvestrant—Body temperature increased—Epirubicin—bone cancer	6.51e-05	0.00181	CcSEcCtD
Fulvestrant—Abdominal pain—Epirubicin—bone cancer	6.51e-05	0.00181	CcSEcCtD
Fulvestrant—Hypersensitivity—Methotrexate—bone cancer	6.49e-05	0.0018	CcSEcCtD
Fulvestrant—ESR1—Signaling by ERBB4—KIT—bone cancer	6.45e-05	0.0013	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—EIF2S1—bone cancer	6.34e-05	0.00128	CbGpPWpGaD
Fulvestrant—Asthenia—Methotrexate—bone cancer	6.32e-05	0.00175	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—DHFR—bone cancer	6.29e-05	0.00127	CbGpPWpGaD
Fulvestrant—Gastrointestinal pain—Doxorubicin—bone cancer	6.23e-05	0.00173	CcSEcCtD
Fulvestrant—Pruritus—Methotrexate—bone cancer	6.23e-05	0.00173	CcSEcCtD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—BRAF—bone cancer	6.09e-05	0.00123	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Epirubicin—bone cancer	6.07e-05	0.00168	CcSEcCtD
Fulvestrant—Urticaria—Doxorubicin—bone cancer	6.06e-05	0.00168	CcSEcCtD
Fulvestrant—Body temperature increased—Doxorubicin—bone cancer	6.03e-05	0.00167	CcSEcCtD
Fulvestrant—Abdominal pain—Doxorubicin—bone cancer	6.03e-05	0.00167	CcSEcCtD
Fulvestrant—Diarrhoea—Methotrexate—bone cancer	6.02e-05	0.00167	CcSEcCtD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—RB1—bone cancer	5.99e-05	0.00121	CbGpPWpGaD
Fulvestrant—Asthenia—Epirubicin—bone cancer	5.91e-05	0.00164	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—GNA11—bone cancer	5.88e-05	0.00119	CbGpPWpGaD
Fulvestrant—Pruritus—Epirubicin—bone cancer	5.83e-05	0.00162	CcSEcCtD
Fulvestrant—Dizziness—Methotrexate—bone cancer	5.82e-05	0.00162	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	5.73e-05	0.00116	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—GSTP1—bone cancer	5.71e-05	0.00115	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	5.71e-05	0.00115	CbGpPWpGaD
Fulvestrant—Diarrhoea—Epirubicin—bone cancer	5.64e-05	0.00156	CcSEcCtD
Fulvestrant—Hypersensitivity—Doxorubicin—bone cancer	5.62e-05	0.00156	CcSEcCtD
Fulvestrant—Vomiting—Methotrexate—bone cancer	5.6e-05	0.00155	CcSEcCtD
Fulvestrant—Rash—Methotrexate—bone cancer	5.55e-05	0.00154	CcSEcCtD
Fulvestrant—Dermatitis—Methotrexate—bone cancer	5.55e-05	0.00154	CcSEcCtD
Fulvestrant—ESR2—Gene Expression—EIF2S1—bone cancer	5.52e-05	0.00111	CbGpPWpGaD
Fulvestrant—Headache—Methotrexate—bone cancer	5.51e-05	0.00153	CcSEcCtD
Fulvestrant—NR1H4—Gene Expression—EZH2—bone cancer	5.5e-05	0.00111	CbGpPWpGaD
Fulvestrant—Asthenia—Doxorubicin—bone cancer	5.47e-05	0.00152	CcSEcCtD
Fulvestrant—Dizziness—Epirubicin—bone cancer	5.45e-05	0.00151	CcSEcCtD
Fulvestrant—ESR1—Gene Expression—FUS—bone cancer	5.44e-05	0.0011	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—TP53—bone cancer	5.42e-05	0.00109	CbGpPWpGaD
Fulvestrant—Pruritus—Doxorubicin—bone cancer	5.39e-05	0.0015	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—CYP3A4—bone cancer	5.33e-05	0.00108	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	5.31e-05	0.00107	CbGpPWpGaD
Fulvestrant—Vomiting—Epirubicin—bone cancer	5.24e-05	0.00145	CcSEcCtD
Fulvestrant—Nausea—Methotrexate—bone cancer	5.23e-05	0.00145	CcSEcCtD
Fulvestrant—Diarrhoea—Doxorubicin—bone cancer	5.22e-05	0.00145	CcSEcCtD
Fulvestrant—Rash—Epirubicin—bone cancer	5.19e-05	0.00144	CcSEcCtD
Fulvestrant—Dermatitis—Epirubicin—bone cancer	5.19e-05	0.00144	CcSEcCtD
Fulvestrant—Headache—Epirubicin—bone cancer	5.16e-05	0.00143	CcSEcCtD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—MDM2—bone cancer	5.11e-05	0.00103	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—MDM2—bone cancer	5.08e-05	0.00102	CbGpPWpGaD
Fulvestrant—Dizziness—Doxorubicin—bone cancer	5.04e-05	0.0014	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—ENO2—bone cancer	4.96e-05	0.001	CbGpPWpGaD
Fulvestrant—Nausea—Epirubicin—bone cancer	4.89e-05	0.00136	CcSEcCtD
Fulvestrant—Vomiting—Doxorubicin—bone cancer	4.85e-05	0.00135	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	4.81e-05	0.000971	CbGpPWpGaD
Fulvestrant—Rash—Doxorubicin—bone cancer	4.81e-05	0.00133	CcSEcCtD
Fulvestrant—Dermatitis—Doxorubicin—bone cancer	4.8e-05	0.00133	CcSEcCtD
Fulvestrant—ESR2—Gene Expression—EZH2—bone cancer	4.79e-05	0.000967	CbGpPWpGaD
Fulvestrant—Headache—Doxorubicin—bone cancer	4.78e-05	0.00133	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—DHFR—bone cancer	4.6e-05	0.000928	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—GSTP1—bone cancer	4.56e-05	0.00092	CbGpPWpGaD
Fulvestrant—Nausea—Doxorubicin—bone cancer	4.53e-05	0.00126	CcSEcCtD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—JUN—bone cancer	4.44e-05	0.000895	CbGpPWpGaD
Fulvestrant—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	4.31e-05	0.000869	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—GNA11—bone cancer	4.3e-05	0.000867	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	4.23e-05	0.000853	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	4.08e-05	0.000822	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—CYP3A4—bone cancer	3.9e-05	0.000786	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.88e-05	0.000782	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—NR1I2—bone cancer	3.77e-05	0.00076	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	3.68e-05	0.000742	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—EGFR—bone cancer	3.49e-05	0.000704	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—EGFR—bone cancer	3.47e-05	0.0007	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—GSTP1—bone cancer	3.33e-05	0.000672	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PTGS2—bone cancer	2.96e-05	0.000596	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—TP53—bone cancer	2.93e-05	0.000591	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.89e-05	0.000583	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—RGS1—bone cancer	2.83e-05	0.00057	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—GRM4—bone cancer	2.83e-05	0.00057	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—GSTP1—bone cancer	2.79e-05	0.000563	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—EIF2S1—bone cancer	2.78e-05	0.000561	CbGpPWpGaD
Fulvestrant—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	2.75e-05	0.000555	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—GRM1—bone cancer	2.45e-05	0.000494	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.43e-05	0.000489	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—EZH2—bone cancer	2.42e-05	0.000487	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PTGS2—bone cancer	2.36e-05	0.000477	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—NDUFA12—bone cancer	1.96e-05	0.000394	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PTGS2—bone cancer	1.73e-05	0.000348	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—SMO—bone cancer	1.73e-05	0.000348	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—NT5C3A—bone cancer	1.62e-05	0.000327	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—GNA11—bone cancer	1.58e-05	0.000318	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—ATF1—bone cancer	1.47e-05	0.000296	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IL3—bone cancer	1.43e-05	0.000289	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TGFBR2—bone cancer	1.22e-05	0.000247	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IGF1R—bone cancer	1.15e-05	0.000232	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—KIT—bone cancer	8.35e-06	0.000168	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—BRAF—bone cancer	7.85e-06	0.000158	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ENO2—bone cancer	7.1e-06	0.000143	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—DHFR—bone cancer	6.58e-06	0.000133	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MDM2—bone cancer	6.58e-06	0.000133	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GNA11—bone cancer	6.15e-06	0.000124	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—JUN—bone cancer	5.72e-06	0.000115	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MMP9—bone cancer	5.56e-06	0.000112	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GSTP1—bone cancer	4.77e-06	9.62e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—EGFR—bone cancer	4.5e-06	9.07e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TP53—bone cancer	3.77e-06	7.61e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PTGS2—bone cancer	2.47e-06	4.99e-05	CbGpPWpGaD
